FORM 4

obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: Estimated average burden 0.5 hours per response:

OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MARSHBANKS TRACY						2. Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ANIP]								(Che	ck all app	l applicable) Director		10% Owner	
(Last) (First) (Middle) C/O ANI PHARMACEUTICALS, INC						3. Date of Earliest Transaction (Month/Day/Year) 05/09/2018									Officer (give titl below)			e Other (specify below)	
Street) BAUDETTE MN 56623 (City) (State) (Zip)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	,				
		Tabl	e I - N	on-Deriv	ative	Sec	uritie	s Ac	quire	d, Di	sposed o	f, or B	enefic	ially	Owne	ed			
1. Title of Security (Instr. 3)				Date		Execution Date,		3. Transaction Code (Instr. 8)					d 5) Securities Beneficial Owned Fo		ies :ially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price		Transac	ction(s)			(Instr. 4)
Common Stock				05/09/2018				S		20,517	D	\$62.0	05(1)	43	430,084		T I	See Footnote ⁽⁴⁾	
Common Stock				05/10/2018				S		17,685	D	\$62.	14 ⁽²⁾	412,399				See Footnote ⁽⁴⁾	
Common Stock				05/10/2018					S		24,229	D	\$62.0	\$62.03 ⁽³⁾		388,170			See Footnote ⁽⁴⁾
		Та	ble II												wned				
rivative Conversion Date Execution curity or Exercise (Month/Day/Year) if any		on Date, Transac Code (In			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expira (Monti	ation D	ate Year)	Amount or Number		Derivative Security (Instr. 5)		derivative Securities Beneficial Owned Following Reported	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
	(I PHARM IN STREE TTE M (Security (In Stock Stock Stock 2. Conversion or Exercise Price of Derivative	(First) I PHARMACEUT IN STREET WEST TTE MN (State) Security (Instr. 3) Stock Stock 2. Conversion or Exercise Price of Derivative	(First) (I PHARMACEUTICALS, II IN STREET WEST TTE MN 5 (State) (Table Security (Instr. 3) Stock Stock Table Stock Stock Table Stock Table Security (Instr. 3)	(First) (Middle) I PHARMACEUTICALS, INC IN STREET WEST TTE MN 56623 (State) (Zip) Table I - N Security (Instr. 3) Stock Stock Table II 2. Conversion or Exercise Price of Derivative (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	(First) (Middle) I PHARMACEUTICALS, INC IN STREET WEST TTE MN 56623 (State) (Zip) Table I - Non-Derive (Month/Day) Security (Instr. 3) Stock 05/09/2 Stock 05/10/2 Table II - Derivate (e.g., put (e.g., put (e.g., put (Month/Day)Year)) Z. Transaction Date (Month/Day/Year) Stock 05/10/2	(First) (Middle) I PHARMACEUTICALS, INC IN STREET WEST Table I - Non-Derivative Security (Instr. 3) Stock Conversion or Exercise Price of Derivative Conversion or Exercise Price of Derivative 2. Transaction Date (Month/Day/Year) 3. C (Middle) 3. C (Middle) 5. C (Middle) 6. C (Middle) 7. C (Middle) 8. C (Middl	(First) (Middle) I PHARMACEUTICALS, INC IN STREET WEST Table I - Non-Derivative Security (Instr. 3) Table I - Non-Derivative Security (Month/Day/Year) Stock Table II - Derivative Security (e.g., puts, calls, (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, (Month/Day/Year) ANI PI 3. Date of 05/09/20 4. If Amendate (Month/Day/Year) Table II - Derivative Security (Month/Day/Year) Table III - Derivative Security (e.g., puts, calls, (Month/Day/Year) ANI PI 3. Date of 05/09/20 4. If Amendate (Month/Day/Year) Table II - Derivative Security (e.g., puts, calls, (Month/Day/Year) ANI PI 3. Date of 05/09/20 4. If Amendate (Month/Day/Year) ANI PI 4. If Amendate (Month/Day/Year)	(First) (Middle) I PHARMACEUTICALS, INC IN STREET WEST Table I - Non-Derivative Securitie Security (Instr. 3) Table I - Non-Derivative Securitie (Month/Day/Year) Stock O5/09/2018 2. Transaction Date (Month/Day/Year) Stock Table II - Derivative Securities (e.g., puts, calls, warrange) Table II - Derivative Securities (e.g., puts, calls, warrange) Table II - Derivative Securities (e.g., puts, calls, warrange) 2. Table II - Derivative Securities (e.g., puts, calls, warrange) ANI PHARMACEUTICALS 4. If Amendment, I part of Earlies (D5/09/2018) Stock O5/09/2018 Table II - Derivative Securities (e.g., puts, calls, warrange) 2. Table II - Derivative Securities (e.g., puts, calls, warrange) Date (Month/Day/Year) Of Derivative Security (Month/Day/Year) Of Derivative Security (Instr. 8)	Conversion of Exercise Price of Derivative Security (Month/Day/Year) Stock Conversion of Exercise Price of Derivative Security (Month/Day/Year) Conversion of Date (Month/Day/Year) Conversion Date (Month/Day/Year) Co	(First) (Middle) I PHARMACEUTICALS, INC IN STREET WEST Table I - Non-Derivative Securities Acquire (Month/Day/Year) Security (Instr. 3) Table I - Non-Derivative Securities Acquire (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) Stock Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, option or Exercise Price of Derivative Security Conversion or Exercise Price of Derivative Securities Acquired (Month/Day/Year) 2. Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, option or Exercise Price of Derivative Security Stock 3. Transaction Date (e.g., puts, calls, warrants, option or Exercise Price of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4) Conversion or Exercise Price of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4)	ANI PHARMACEUTICALS	ANI PHARMACEUTICALS INC	ANI PHARMACEUTICALS INC Stock St	ANI PHARMACEUTICALS INC ANIP	ANI PHARMACEUTICALS INC [ANIP] (First) (Middle) I PHARMACEUTICALS, INC IN STREET WEST Table 1 - Non-Derivative Securities Acquired, Disposed of, or Beneficially Security (Instr. 3) 2. Transaction 2. Tra	ANI PHARMACEUTICALS INC ANIP Check all app X Direct	ANI PHARMACEUTICALS INC (First) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle) (Middle	ANI PHARMACEUTICALS INC [ANIP] (First) (Middle) I PHARMACEUTICALS, INC IN STREET WEST TITE MN 56623 (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year) Security (Instr. 3) Date of Earliest Transaction (Month/Day/Year) A. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year) Security (Instr. 3) Date of Earliest Transaction (Month/Day/Year) A. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned (Month/Day/Year) Code V Amount (A) or Disposed of (D) (Instr. 3, 4 and 5) Securities Securities	ANI PHARMACEUTICALS INC (First) (Middle) (First) (Middle) (First) (Middle) (First) (Middle) (First) (Middle) (Middle)

Explanation of Responses:

- 1. This transaction was executed in multiple trades at prices ranging from \$62.00 to \$62.335. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 2. This transaction was executed in multiple trades at prices ranging from \$62.00 to \$62.5425. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 3. This transaction was executed in multiple trades at prices ranging from \$62.00 to \$62.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 4. Held by FA Private Equity Fund IV, L.P., FA Private Equity Fund IV GmbH & Co. Beteiligungs KG, The Productivity Fund IV Liquidating Trust, and The Productivity Fund IV Advisors Fund Liquidating Trust, which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).

/s/ Tracy Marshbanks

05/11/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.